Cytokinetics Share Price (NASDAQ: CYTK)

$37.72

▲

-0.11

(-0.29%)

Live

Last updated on August 29, 2025 at 1:29 am IST

$₹

Check the interactive Cytokinetics Stock chart to analyse performance

Cytokinetics stock performance

as on August 29, 2025 at 1:29 am IST

Today's Low:$37.69
Today's High:$39.90
$37.72
0.08%
Downside
Day's Volatility :5.54%
Upside
5.46%
52 Weeks Low:$29.31
52 Weeks High:$59.39
$37.72
22.3%
Downside
52 Weeks Volatility :50.65%
Upside
36.49%

Cytokinetics Stock Returns

Period	Cytokinetics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	20.79%	4.2%	0.0%
6 Months	-20.27%	-8.0%	0.0%
1 Year	-31.87%	-12.1%	0.0%
3 Years	-26.07%	7.6%	-6.9%

Cytokinetics Inc Key Stats

Check Cytokinetics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$37.83
Open	$37.66
Today's High	$39.9
Today's Low	$37.34
Market Capitalization	$4.6B
Today's Volume	$2.2M
52 Week High	$59.39
52 Week Low	$29.31
Revenue TTM	$85.7M
EBITDA	$-537.6M
Earnings Per Share (EPS)	$-5.12
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-572.15%

Stock Returns calculator for Cytokinetics Stock including INR - Dollar returns

The Cytokinetics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Cytokinetics investment value today

Current value as on today

₹72,358

Returns

₹27,642

(-27.64%)

Returns from Cytokinetics Stock

₹32,073 (-32.07%)

Dollar Returns*

₹4,430 (+4.43%)

Indian investors sentiment towards Cytokinetics Stock

-22%

Period: Jul 29, 2025 to Aug 28, 2025. Change in 30 Days versus previous period

Search interest for Cytokinetics Stock from India on INDmoney has decreased by -22% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Cytokinetics Inc

Name
Holdings %
Name
Holdings %
T. Rowe Price Investment Management,Inc.
14.72%
BlackRock Inc
13.01%
Vanguard Group Inc
10.02%
FMR Inc
8.63%
Wellington Management Company LLP
6.54%
State Street Corp
5.09%

Analyst Recommendation on Cytokinetics Stock

Rating

Trend

Buy

84%Buy

16%Hold

0%Sell

Based on 25 Wall street analysts offering stock ratings for Cytokinetics(by analysts ranked 0 to 5 stars)

Cytokinetics Share Price Target

What analysts predicted

Upside of 88.37%

Target:

$71.05

Current:

$37.72

Cytokinetics share price target is $71.05, a slight Upside of 88.37% compared to current price of $37.72 as per analysts' prediction.

Cytokinetics Stock Insights

Price Movement
In the last 7 days, CYTK stock has moved down by -0.6%
Increasing Revenue
Revenue is up for the last 2 quarters, 1.57M → 66.76M (in $), with an average increase of 97.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -161.37M → -134.37M (in $), with an average increase of 20.1% per quarter
CYTK vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 61.8% return, outperforming this stock by 93.7%
CYTK vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 115.3% return, outperforming this stock by 141.2%
Price to Sales
ForCYTK every $1 of sales, investors are willing to pay $52.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Cytokinetics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$26.9M	↓ 14.71%
Net Income	$-121.7M	↑ 14.49%
Net Profit Margin	-452.93%	↓ 115.52%

	FY20	Y/Y Change
Revenue	$55.8M	↑ 107.79%
Net Income	$-127.3M	↑ 4.6%
Net Profit Margin	-228.0%	↑ 224.93%

	FY21	Y/Y Change
Revenue	$70.4M	↑ 26.15%
Net Income	$-215.3M	↑ 69.15%
Net Profit Margin	-305.72%	↓ 77.72%

	FY22	Y/Y Change
Revenue	$94.6M	↑ 34.3%
Net Income	$-389.0M	↑ 80.65%
Net Profit Margin	-411.21%	↓ 105.49%

	FY23	Y/Y Change
Revenue	$7.5M	↓ 92.04%
Net Income	$-526.2M	↑ 35.3%
Net Profit Margin	-7.0K%	↓ 6577.42%

	FY24	Y/Y Change
Revenue	$18.5M	↑ 145.34%
Net Income	$-589.5M	↑ 12.03%
Net Profit Margin	-3.2K%	↑ 3797.52%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$835.0K	↓ 50.06%
Net Income	$-135.6M	↓ 0.92%
Net Profit Margin	-16.2K%	↓ 8057.11%

	Q2 FY24	Q/Q Change
Revenue	$249.0K	↓ 70.18%
Net Income	$-143.3M	↑ 5.66%
Net Profit Margin	-57.6K%	↓ 41312.76%

	Q3 FY24	Q/Q Change
Revenue	$463.0K	↑ 85.94%
Net Income	$-160.5M	↑ 12.02%
Net Profit Margin	-34.7K%	↑ 22882.48%

	Q4 FY24	Q/Q Change
Revenue	$16.9M	↑ 3555.94%
Net Income	$-150.0M	↓ 6.56%
Net Profit Margin	-886.28%	↑ 33788.67%

	Q1 FY25	Q/Q Change
Revenue	$1.6M	↓ 90.67%
Net Income	$-161.4M	↑ 7.57%
Net Profit Margin	-10.2K%	↓ 9333.86%

	Q2 FY25	Q/Q Change
Revenue	$66.8M	↑ 4128.56%
Net Income	$-134.4M	↓ 16.73%
Net Profit Margin	-201.25%	↑ 10018.89%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-59.3M	↑ 2.82%

	FY20	Y/Y Change
Profit	$-41.1M	↓ 30.6%

	FY21	Y/Y Change
Profit	$-89.5M	↑ 117.66%

	FY22	Y/Y Change
Profit	$-146.2M	↑ 63.36%

	FY23	Y/Y Change
Profit	$-322.6M	↑ 120.61%

	FY24	Y/Y Change
Profit	$-320.9M	↓ 0.51%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-1.5M	↓ 67.92%

	Q2 FY24	Q/Q Change
Profit	$-2.2M	↑ 44.18%

	Q3 FY24	Q/Q Change
Profit	$-84.1M	↑ 3801.21%

	Q4 FY24	Q/Q Change
Profit	$-76.7M	↓ 8.85%

	Q1 FY25	Q/Q Change
Profit	$-98.3M	↑ 28.11%

	Q2 FY25	Q/Q Change
Profit	$64.5M	↓ 165.62%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-90.9M	↓ 10.18%
Investing Cash Flow	$-74.7M	↓ 1555.43%
Financing Cash Flow	$159.8M	↑ 1116.81%

	FY20	Y/Y Change
Operating Cash Flow	$8.9M	↓ 109.84%
Investing Cash Flow	$-196.5M	↑ 163.05%
Financing Cash Flow	$234.1M	↑ 46.52%

	FY21	Y/Y Change
Operating Cash Flow	$-142.5M	↓ 1693.67%
Investing Cash Flow	$-147.8M	↓ 24.8%
Financing Cash Flow	$320.0M	↑ 36.67%

	FY22	Y/Y Change
Operating Cash Flow	$-299.5M	↑ 110.15%
Investing Cash Flow	$-262.1M	↑ 77.38%
Financing Cash Flow	$516.2M	↑ 61.31%

	FY23	Y/Y Change
Operating Cash Flow	$-414.3M	↑ 38.33%
Investing Cash Flow	$239.3M	↓ 191.27%
Financing Cash Flow	$221.3M	↓ 57.12%

	FY24	Y/Y Change
Operating Cash Flow	$-395.9M	↓ 4.45%
Investing Cash Flow	$-553.1M	↓ 331.18%
Financing Cash Flow	$930.6M	↑ 320.49%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-129.5M	↑ 74.92%
Investing Cash Flow	$32.6M	↓ 140.09%
Financing Cash Flow	$103.8M	↓ 38.51%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-99.3M	↓ 23.31%
Investing Cash Flow	$-651.5M	↓ 2096.1%
Financing Cash Flow	$821.0M	↑ 691.02%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-101.5M	↑ 2.2%
Investing Cash Flow	$-45.1M	↓ 93.09%
Financing Cash Flow	$3.4M	↓ 99.58%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-65.6M	↓ 35.4%
Investing Cash Flow	$110.9M	↓ 346.07%
Financing Cash Flow	$2.4M	↓ 30.39%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-131.6M	↑ 100.73%
Investing Cash Flow	$106.0M	↓ 4.43%
Financing Cash Flow	$4.8M	↑ 99.41%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-128.2M	↓ 2.57%
Investing Cash Flow	$52.9M	↓ 50.09%
Financing Cash Flow	$78.5M	↑ 1551.94%

Cytokinetics Technicals Summary

Sell

Neutral

Buy

Cytokinetics is currently in a neutral trading position according to technical analysis indicators.

Cytokinetics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Cytokinetics Inc	5.38%	-20.27%	-31.87%	-26.07%	57.89%
Regeneron Pharmaceuticals, Inc.	5.16%	-16.48%	-51.06%	-0.98%	-5.32%
Beone Medicines Ltd	-1.83%	7.82%	51.46%	79.4%	24.25%
Vertex Pharmaceuticals Incorporated	-16.94%	-18.0%	-20.55%	38.17%	39.4%
Alnylam Pharmaceuticals, Inc.	37.4%	91.56%	61.8%	117.28%	242.42%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Cytokinetics Inc	NA	NA	-0.42	-5.57	-5.72	-0.25	NA	-3.08
Regeneron Pharmaceuticals, Inc.	14.86	14.86	1.21	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.58	27.58	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Cytokinetics Inc	Buy	$4.6B	57.89%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$62.5B	-5.32%	14.86	31.37%
Beone Medicines Ltd	NA	$37.7B	24.25%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$99.3B	39.4%	27.58	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.1B	242.42%	NA	-12.96%

Cytokinetics Dividend announcements

Cytokinetics Earnings
Cytokinetics’s price-to-earnings ratio stands at None

About Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Organization	Cytokinetics
Employees	498
CEO	Mr. Robert I. Blum
Industry	Health Technology

Key Management of Cytokinetics Inc

Name	Title
Mr. Robert I. Blum	CEO, President & Director
Dr. Fady Ibraham Malik FACC, M.D., Ph.D.	Executive Vice President of Research & Development
Mr. Andrew M. Callos	Executive VP & Chief Commercial Officer
Dr. James A. Spudich Ph.D.	Co-Founder & Member of Scientific Advisory Board
Mr. Jeff Lotz	Vice President of Sales & Operations
Ms. Holly Laughlin	VP of Accounting & Corporate Controller
Mr. Steven M. Cook J.D.	Senior Vice President of Global Supply Chain Operations & Technical Operations
Ms. Kari K. Loeser J.D.	VP & Chief Compliance Officer
Ms. Laura Robertson M.D.	Medical Director of Clinical
Ms. Jennifer Laux M.B.A.	VP of Cardiovascular Marketing

Important FAQs about investing in CYTK Stock from India :

What is Cytokinetics share price today?

Cytokinetics share price today is $37.72 as on August 29, 2025 at 1:29 am IST. Cytokinetics share today touched a day high of $39.90 and a low of $37.69.

What is the 52 week high and 52 week low for Cytokinetics share?

Cytokinetics share touched a 52 week high of $59.39 and a 52 week low of $29.31. Cytokinetics stock price today i.e. August 29, 2025 at 1:29 am IST is trending at $37.72, lower by 36.49% versus the 52 week high.

How to invest in Cytokinetics Stock (CYTK) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Cytokinetics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cytokinetics Shares that will get you 0.0398 shares as per Cytokinetics share price of $37.72 per share as on August 29, 2025 at 1:29 am IST.

What is the minimum amount required to buy Cytokinetics Stock (CYTK) from India?

Indian investors can start investing in Cytokinetics (CYTK) shares with as little as ₹87.6463 or $1 (as of August 29, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹876.46 in Cytokinetics stock (as per the Rupee-Dollar exchange rate as on August 29, 2025). Based on Cytokinetics share’s latest price of $37.72 as on August 29, 2025 at 1:29 am IST, you will get 0.2651 shares of Cytokinetics. Learn more about fractional shares .

What are the returns that Cytokinetics has given to Indian investors in the last 5 years?

Cytokinetics stock has given 57.89% share price returns and 18.6% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?